Urofollitropin
- Atc Codes:G03GA04
- CAS Codes:97048-13-0
- PHARMGKB ID:97048-13-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Bravelle, Fostimon; Belgium: Fostimon; Bulgaria: Bravelle, Fostimon; Czech Republic: Bravelle, Fostimon; Denmark: Bravelle, Fostimon; Estonia: Bravelle; Finland: Fostimon; France: Fostimon; Germany: Bravelle, Fertinorm; Greece: Folligon, Metrodin; Hungary: Bravelle; Ireland: Bravelle, Fostimon; Italy: Metrodin; Latvia: Bravelle; Lithuania: Bravelle; Netherlands: Bravelle, Fostimon; Poland: Bravelle, Fostimon, Metrodin; Portugal: Bravelle, Fostimon; Romania: Bravelle; Slovakia: Bravelle, Fostimon; Slovenia: Bravelle; Spain: Bravelle, Fostipur; Sweden: Bravelle, Fostimon.
North America
Canada: Bravelle; USA: Bravelle.
Latin America
Brazil: Metrodin; Mexico: Fostimón.
Drug combinations
Chemistry
Urofollitropin: A preparation of purified extract of human post-menopausal urine containing follicle-stimulating hormone (FSH). CAS-97048-13-0 (1987).
Pharmacologic Category
Hormones and Synthetic Substitutes; Gonadotropins. Ovulation Stimulator. (ATC-Code: G03GA04).
Mechanism of action
A preparation of highly purified follicle-stimulating hormone (FSH) extracted from urine of postmenopausal women. Follitropins stimulate ovarian follicular growth in women who do not have primary ovarian failure.
Therapeutic use
Ovulation induction in patients who previously received pituitary suppression. Development of multiple follicles with assisted reproductive technologies.
Pregnancy and lactiation implications
Ectopic pregnancy, congenital abnormalities, spontaneous abortion, and multiple births reported. Excretion in breast milk unknown (not recommended in nursing women).
Unlabeled use
Contraindications
Hypersensitivity to follitropins or any component of the formulation. High levels of FSH indicating primary ovarian failure. Uncontrolled thyroid or adrenal dysfunction. Presence of any cause of infertility other than anovulation. Presence of organic intracranial lesion (e.g. pituitary tumor). Abnormal vaginal bleeding of undetermined origin. Ovarian cysts or enlargement not due to polycystic ovary syndrome. Pregnancy.
Warnings and precautions
Ovarian enlargement might occur and may be accompanied by abdominal distention or abdominal pain. Ovarian hyperstimulation syndrome, develops rapidly within 24 hours to several days and generally occurs during 7-10 days immediately following treatment. Hemoconcentration associated with fluid loss into abdominal cavity occurred. Serious pulmonary conditions (atelectasis, acute respiratory distress syndrome, and exacerbation of asthma) reported. Thromboembolic events reported. Products may contain lactose. Multiple births may result.